Integrating microbubbles into a CAR-T workflow: more doses in a smaller footprint

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Integrating microbubbles into a CAR-T workflow: more doses in a smaller footprint

Discover how integrating microbubble technology into your CAR-T workflow can improve efficiency, reduce complexity, and enhance therapeutic outcomes, without overhauling your existing setup. Drawing on recent data and practical examples, this webinar will compare a microbubble approach to traditional magnetic particle-based methods.

What you will learn:

Workflow efficiency
Learn how microbubble technology can reduce GMP suite time by over 50%, enabling faster cell isolation or depletion—often in under an hour.

Cell quality and recovery
Understand how the gentle nature of microbubbles contributes to higher cell purity, improved recovery rates, and increased cytotoxicity.

Process simplification
Examine how this method can help reduce process complexity, lower the risk of failure, and support consistent outcomes across development and commercialization stages.

Scalability and flexibility
See how the approach can be implemented using existing equipment or in-bag separation, minimizing the need for additional capital investment.

Join this webinar to gain:

A clear comparison between microbubble and magnetic particle-based separation
Practical strategies to reduce failure risks and turnaround time
Insights into how GMP microbubbles support therapeutic effectiveness
Access to an Evaluation Program to test the technology in your own lab

Alex Sargent

Director, Process Development, Cell and Gene Therapy at Charles River Laboratories

Alex Sargent – better known as “Sarge” – is currently the Director of Process Development at Charles River Laboratories. He obtained his PhD from Case Western Reserve University in Cleveland Ohio, where he studied the challenges and promises of stem cell biology, neuroimmunology, and Cleveland sports teams. After a brief stint in academia at the Cleveland Clinic, he left Cleveland to pursue his industry career in cell therapy. During his many years in this industry, he has had the honor of working at several esteemed enterprises on new technologies and approaches for cell therapy scale up, automation, and gene editing. He is especially passionate about the challenge of curing cancer, working on CAR-T and CAR-NK cell therapy process and analytical development from discovery, through regulatory submission, manufacturing, and pivotal clinical trials. He wakes up each day excited to help advance cell and gene therapy to treat and cure disease, with the steadfast goal of improving human lives.

Crisha Christensen

Field Applications Scientist at Akadeum Life Sciences

Crisha earned a M.S. at the University of Michigan and her B.S. in biology from Ferris State University. She has an accomplished background in immunoassay development and specialized experience in flow cytometry, cell isolation, ELISpot, and immunocytochemistry. Prior to joining Akadeum, Crisha was the leader of a preclinical GLP regulated flow cytometry team at a CRO.

in 37

Days